INSULINREZISTENTLIGI BO‘LGAN BEMORLARDA SEMIZLIK DARAJASIGA BOG‘LIQ HOLDA KOPTOKCHALAR FILTRATSIYASI TEZLIGINING ERTA BUZILISHLARINI ANIQLASH

Maqola yon paneli

PDF (ruscha)
Nashr qilingan: 2024-05-05
Kalit so‘zlar:
SYuYe, SBK, YuQTA, KFT

Maqolaning asosiy mazmuni

Mamadiyorova Mashxura Akbarovna
Samarqand davlat tibbiyot universiteti, O‘zbekiston Respublikasi, Samarqand shahri

Abstrak

Surunkali yurak yetishmovchiligi (SYuYe) davolashda erishilgan sezilarli yutuqlarga qaramay, eng dolzarb tibbiy va ijtimoiy-iqtisodiy muammolardan biri bo‘lib qolmoqda, chunki bu bemorlarning prognozi noxushligicha qolmoqda. Yurak-qon tomir tizimi patologiyasi va buyraklar o‘rtasidagi o‘zaro bog‘liqlikni jadal o‘rganish kardiorenal sindrom konsepsiyasining yaratilishiga olib keldi.

Maqola tafsilotlari

Nashr

Jild 3 Nomeri 4 (2024): Research Focus International Scientific Journal. 3-tom, 4-son (2024)

Bo'lim

14.00.00 – Tibbiyot fanlari
Creative Commons litsenziyasi

Ushbu asar Creative Commons Attribution 4.0 International litsenziyasi asosida litsenziyalangan.

Qanday iqtibos keltirish kerak

INSULINREZISTENTLIGI BO‘LGAN BEMORLARDA SEMIZLIK DARAJASIGA BOG‘LIQ HOLDA KOPTOKCHALAR FILTRATSIYASI TEZLIGINING ERTA BUZILISHLARINI ANIQLASH. (2024). Research Focus International Scientific Journal, 3(4), 195-201. https://refocus.uz/index.php/rf/article/view/2674

Adabiyotlar

Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, Clark JM, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol (2016) 4(11):913–21.

Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (2021) 398(10295):143–55. doi: 10.1016/S0140-6736(21)01324-6

Шилов Е.М. и др.Новые подходы к лечению больных хронической болезнью почек и метаболическим синдромом // Клиническая нефрология. 2012. № 2. С. 72–76.)

Friedman AN, Kaplan LM, le Roux CW, Schauer PR. Management of obesity in adults with CKD. J Am Soc Nephrology (2021) 32(4):777–90. doi: 10.1681/ASN.2020101472

Tesauro M, Mascali A, Franzese O, Cipriani S, Cardillo C, Di Daniele N. Chronic kidney disease, obesity, and hypertension: the role of leptin and adiponectin. Int J Hypertens (2012) 2012:943605. doi: 10.1155/2012/943605

Baylis D, Bartlett DB, Patel HP, Roberts HC. Understanding how we age: insights into inflammaging. Longevity Healthspan (2013) 2(1):8. doi: 10.1186/2046-2395-2-8

Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med (1995) 122(7):481–6. doi: 10.7326/0003-4819-122- 7-199504010-00001

Ahima RS. Connecting obesity, aging and diabetes. Nat Med (2009) 15(9):996–7. doi: 10.1038/nm0909-996

Tchkonia T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, Scrable H, et al. Fat tissue, aging, and cellular senescence. Aging Cell (2010) 9(5):667–84. doi: 10.1111/j.1474- 9726.2010.00608.x

Robbins PD, Jurk D, Khosla S, Kirkland JL, LeBrasseur NK, Miller JD, et al. Senolytic drugs: Reducing senescent cell viability to extend health span. Annu Rev Pharmacol Toxicol (2021) 61:779–803. doi: 10.1146/annurev-pharmtox-050120-105018

Lair B, Laurens C, Van Den Bosch B, Moro C. Novel insights and mechanisms of lipotoxicity-driven insulin resistance. Int J Mol Sci [Internet] (2020) 21(17). doi: 10.3390/ijms21176358

Palmer AK, Tchkonia T, Kirkland JL. Targeting cellular senescence in metabolic disease. Mol Metab (2022) 66:101601. doi: 10.1016/j.molmet.2022.101601

Tzanavari T, Giannogonas P, Karalis KP. TNF-α and obesity. Current Directions in Autoimmunity (2010) 11:145–156. doi: 10.1159/000289203

Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature (1997) 389(6651):610–4. doi: 10.1038/39335

Lim CC, Teo BW, Tai ES, Lim SC, Chan CM, Sethi S, et al. Elevated serum leptin, adiponectin and leptin to adiponectin ratio is associated with chronic kidney disease in Asian adults. PloS One (2015) 10(3):e0122009. doi: 10.1371/journal.pone.0122009

Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrology (2006) 17(9):2599. doi: 10.1681/ASN.2006040331 CrossRef Full Text | Google Scholar

Porrini E., Bayes B., Diaz Juan M. et al. Hyperinsulinemia and hyperfiltration in renal transplantation // Transplantation. 2009. Vol. 87. № 2. P. 274–279.

Suh SH, Oh TR, Choi HS, Kim CS, Lee J, Oh YK, et al. Association of high serum adiponectin level with adverse cardiovascular outcomes and progression of coronary artery calcification in patients with pre-dialysis chronic kidney disease. Front Cardiovasc Med (2021) 8:789488. doi: 10.3389/fcvm.2021.789488PubMed Abstract | CrossRef Full Text | Google Scholar

Halberg N, Schraw TD, Wang ZV, Kim JY, Yi J, Hamilton MP, et al. Systemic fate of the adipocyte-derived factor adiponectin. Diabetes (2009) 58(9):1961–70. doi: 10.2337/db08-1750

Агабабян Ирина Рубеновна and Юсупова Зумрад Кадамбоевна. Сурункали буйрак етишмовчилиги билан боғлиқ сурункали юрак етишмовчилигининг клиник хусусиятлари. Журнал Проблемы биологии и медицины. 2022. № 6 (140)(декабрь. 2022), 26–30.